DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - NYSE:DBD - US2536512021 - Common Stock
57.41 USD
+1.42 (+2.54%)
57.41 USD
0 (0%)
Overall DBD gets a fundamental rating of 4 out of 10. We evaluated DBD against 34 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has only an average score on both its financial health and profitability. DBD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
DBD had positive earnings in the past year.
DBD had a positive operating cash flow in the past year.
In the past 5 years DBD reported 4 times negative net income.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -0.34%, DBD perfoms like the industry average, outperforming 58.82% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1.18%, DBD is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
DBD's Return On Invested Capital of 8.61% is fine compared to the rest of the industry. DBD outperforms 67.65% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 14.92%.
The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.61%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.34% | ||
| ROE | -1.18% | ||
| ROIC | 8.61% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
DBD has a Operating Margin of 7.32%. This is in the better half of the industry: DBD outperforms 73.53% of its industry peers.
DBD's Operating Margin has improved in the last couple of years.
The Gross Margin of DBD (25.44%) is comparable to the rest of the industry.
DBD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.32% | ||
| PM (TTM) | N/A | ||
| GM | 25.44% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
DBD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, DBD has about the same amount of shares outstanding.
The number of shares outstanding for DBD has been reduced compared to 5 years ago.
Compared to 1 year ago, DBD has an improved debt to assets ratio.
2.2 Solvency
DBD has an Altman-Z score of 1.85. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
DBD has a Altman-Z score of 1.85. This is comparable to the rest of the industry: DBD outperforms 47.06% of its industry peers.
DBD has a debt to FCF ratio of 4.62. This is a neutral value as DBD would need 4.62 years to pay back of all of its debts.
DBD has a Debt to FCF ratio of 4.62. This is in the better half of the industry: DBD outperforms 67.65% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that DBD is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.85, DBD is doing worse than 61.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | 4.62 | ||
| Altman-Z | 1.85 |
ROIC/WACC0.92
WACC9.36%
2.3 Liquidity
A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
DBD has a Current ratio (1.36) which is in line with its industry peers.
DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
DBD has a Quick ratio (0.91) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.20% over the past year.
The Earnings Per Share has been growing by 69.69% on average over the past years. This is a very strong growth
Looking at the last year, DBD shows a decrease in Revenue. The Revenue has decreased by -3.75% in the last year.
The Revenue has been decreasing by -3.18% on average over the past years.
EPS 1Y (TTM)13.2%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-18.26%
Revenue 1Y (TTM)-3.75%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-2.61%
3.2 Future
The Earnings Per Share is expected to grow by 11.87% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.83% on average over the next years.
EPS Next Y-3.58%
EPS Next 2Y13.88%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue Next Year2.09%
Revenue Next 2Y2.41%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.29 indicates a rather expensive valuation of DBD.
Based on the Price/Earnings ratio, DBD is valued a bit cheaper than 76.47% of the companies in the same industry.
DBD's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.69.
With a Price/Forward Earnings ratio of 11.47, the valuation of DBD can be described as very reasonable.
76.47% of the companies in the same industry are more expensive than DBD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.18, DBD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.29 | ||
| Fwd PE | 11.47 |
4.2 Price Multiples
97.06% of the companies in the same industry are more expensive than DBD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, DBD is valued cheaply inside the industry as 82.35% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.43 | ||
| EV/EBITDA | 6.77 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.88%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
57.41
+1.42 (+2.54%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.22%
Inst Owner Change-0.07%
Ins Owners1.78%
Ins Owner Change0.24%
Market Cap2.10B
Analysts82.86
Price Target77.18 (34.44%)
Short Float %2.35%
Short Ratio4.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.65%
Min EPS beat(2)1.76%
Max EPS beat(2)59.55%
EPS beat(4)2
Avg EPS beat(4)0.05%
Min EPS beat(4)-52.17%
Max EPS beat(4)59.55%
EPS beat(8)5
Avg EPS beat(8)9.34%
EPS beat(12)7
Avg EPS beat(12)-88.46%
EPS beat(16)8
Avg EPS beat(16)-91.11%
Revenue beat(2)1
Avg Revenue beat(2)0.84%
Min Revenue beat(2)-1.34%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)-0.11%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.04%
Revenue beat(12)4
Avg Revenue beat(12)-0.96%
Revenue beat(16)4
Avg Revenue beat(16)-2.35%
PT rev (1m)0%
PT rev (3m)4.61%
EPS NQ rev (1m)-3.63%
EPS NQ rev (3m)-13.86%
EPS NY rev (1m)6.5%
EPS NY rev (3m)4.99%
Revenue NQ rev (1m)-1.23%
Revenue NQ rev (3m)-4.02%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.29 | ||
| Fwd PE | 11.47 | ||
| P/S | 0.57 | ||
| P/FCF | 10.43 | ||
| P/OCF | 9.28 | ||
| P/B | 1.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.77 |
EPS(TTM)2.83
EY4.93%
EPS(NY)5.01
Fwd EY8.72%
FCF(TTM)5.5
FCFY9.59%
OCF(TTM)6.18
OCFY10.77%
SpS100.25
BVpS29.95
TBVpS-9.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.34% | ||
| ROE | -1.18% | ||
| ROCE | 10.9% | ||
| ROIC | 8.61% | ||
| ROICexc | 9.77% | ||
| ROICexgc | 29.69% | ||
| OM | 7.32% | ||
| PM (TTM) | N/A | ||
| GM | 25.44% | ||
| FCFM | 5.49% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexcg growth 3Y-11.73%
ROICexcg growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score4
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.85 | ||
| Debt/FCF | 4.62 | ||
| Debt/EBITDA | 2.31 | ||
| Cap/Depr | 18.6% | ||
| Cap/Sales | 0.68% | ||
| Interest Coverage | 2.84 | ||
| Cash Conversion | 56.26% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z | 1.85 |
F-Score4
WACC9.36%
ROIC/WACC0.92
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.2%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-18.26%
EPS Next Y-3.58%
EPS Next 2Y13.88%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.75%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-2.61%
Revenue Next Year2.09%
Revenue Next 2Y2.41%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
EBIT growth 1Y3.35%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.77%
EBIT Next 3Y13.69%
EBIT Next 5YN/A
FCF growth 1Y145.49%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y154.49%
OCF growth 3Y6.68%
OCF growth 5Y26.59%